Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/j.1349-7006.2000.tb00902.x http://scihub22266oqcxt.onion/10.1111/j.1349-7006.2000.tb00902.x C5926290!5926290 !11092984     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=11092984 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\11092984 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Jpn+J+Cancer+Res 2000 ; 91 (11 ): 1177-84 Nephropedia Template TP {{tp|p=11092984 |t=2000. Expression of tumor-rejection antigens in gynecologic cancers |pdf=|usr=}}{{11092984 }} gab.com Text Expression of tumor-rejection antigens in gynecologic cancers JO: Jpn J Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=11092984 #FOAvip We recently reported the four tumor-rejection antigens (SART1(259), SART2, SART3, and ART4) that possess tumor epitopes capable of inducing HLA-A2402-restricted cytotoxic T lymphocytes (CTLs) in cancer patients. This study investigated the expression of these tumor antigens in gynecologic cancers, including 33 ovarian cancers, 38 cervical cancers, and 40 endometrial cancers. SART1(259) antigen was detected in 56%, 35%, and 30% of ovarian, cervical and endometrial cancers, while SART2 antigen was detected in 46%, 66%, and 30% of these cancers, respectively. Both SART3 and ART4 antigens were detectable in the majority of these gynecologic cancers tested. In contrast, none of these antigens was detectable in any of the normal ovarian and uterine tissues tested. Peripheral blood mononuclear cells (PBMCs) of HLA-A24(+) patients with gynecologic cancers were found to produce significant levels of interferon-gamma in response to HLA-A24(+) SART3(+) gynecologic cancer cells after having been stimulated three times in vitro with either SART3(109 - 118) or SART3(315 - 323) peptide. These PBMCs lysed HLA-A24(+) SART3(+) gynecologic cancer cells, but not HLA-A24(-) SART3(+) gynecologic cancer cells or HLA-A24(+) normal cells. Therefore, these four antigens and their peptides, including SART3 peptides, would be appropriate molecules for use in specific immunotherapy of HLA-A24(+) gynecologic cancer patients. Twit Text FOAVip Expression of tumor-rejection antigens in gynecologic cancers ????Jpn J Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=11092984 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=11092984 #FOAvip English Wikipedia <ref>{{Cite pmid|11092984 }}</ref> Expression of tumor-rejection antigens in gynecologic cancers #MMPMID11092984 Tanaka S ; Tsuda N ; Kawano K ; Sakamoto M ; Nishida T ; Hashimoto T ; Shichijo S ; Kamura T ; Itoh K Jpn J Cancer Res 2000[Nov]; 91 (11 ): 1177-84 PMID11092984 show ga We recently reported the four tumor-rejection antigens (SART1(259), SART2, SART3, and ART4) that possess tumor epitopes capable of inducing HLA-A2402-restricted cytotoxic T lymphocytes (CTLs) in cancer patients. This study investigated the expression of these tumor antigens in gynecologic cancers, including 33 ovarian cancers, 38 cervical cancers, and 40 endometrial cancers. SART1(259) antigen was detected in 56%, 35%, and 30% of ovarian, cervical and endometrial cancers, while SART2 antigen was detected in 46%, 66%, and 30% of these cancers, respectively. Both SART3 and ART4 antigens were detectable in the majority of these gynecologic cancers tested. In contrast, none of these antigens was detectable in any of the normal ovarian and uterine tissues tested. Peripheral blood mononuclear cells (PBMCs) of HLA-A24(+) patients with gynecologic cancers were found to produce significant levels of interferon-gamma in response to HLA-A24(+) SART3(+) gynecologic cancer cells after having been stimulated three times in vitro with either SART3(109 - 118) or SART3(315 - 323) peptide. These PBMCs lysed HLA-A24(+) SART3(+) gynecologic cancer cells, but not HLA-A24(-) SART3(+) gynecologic cancer cells or HLA-A24(+) normal cells. Therefore, these four antigens and their peptides, including SART3 peptides, would be appropriate molecules for use in specific immunotherapy of HLA-A24(+) gynecologic cancer patients. |*DNA-Binding Proteins [MESH] |*Ribonucleoproteins, Small Nuclear [MESH] |Antigens, Neoplasm/*biosynthesis/immunology [MESH] |Female [MESH] |Genital Neoplasms, Female/*immunology/metabolism [MESH] |Humans [MESH] |Lymphocyte Activation/drug effects/immunology [MESH] |Neoplasm Proteins/biosynthesis/immunology [MESH] |Peptide Fragments/immunology/pharmacology [MESH] |RNA-Binding Proteins/biosynthesis [MESH]Expression of tumor-rejection antigens in gynecologic cancers (epmc).pdf DeepDyve Pubget Overpricing